Form 4 for KLRS Kalaris Therapeutics, Inc.
Accepted 2022-11-14 00:00:00 ET · period of report 2022-11-10 · accession 0000899243-22-035701 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-11-14 | 2022-11-10+ | KLRS | Hagen Brett R | CAO | S - Sale | $8.14 | -24.0K | 75.9K | -24% | -$195.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-10 | S | D | 5,989 | $8.00 | 93,910 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.015. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 2 | Common | Common Stock | 2022-11-11 | S | D | 18,011 | $8.18 | 75,899 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.49. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |